Retrospective Chart Review of Children With Wiskott-Aldrich Syndrome Who Received Romiplostim in Treatment of Thrombocytopenia.
Latest Information Update: 03 Oct 2021
Price :
$35 *
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenia; Wiskott-Aldrich syndrome
- Focus Therapeutic Use
- 24 Dec 2020 Status changed from active, no longer recruiting to completed.
- 04 May 2020 Planned End Date changed from 1 Apr 2020 to 1 Jun 2020.
- 20 Apr 2020 New trial record